Data gathered: October 14
Alternative Data for Eliem Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 85 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 406 | Sign up | Sign up | Sign up |
| Twitter Mentions | 21 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Eliem Therapeutics
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other central nervous system disorders. and peripheral in the United States. The company is headquartered in Redmond, Washington.
| Price | $5.11 |
| Target Price | Sign up |
| Volume | 803,920 |
| Market Cap | $343M |
| Year Range | $2.54 - $10.2 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Renaissance Technologies LLC Raises Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)October 13 - ETF Daily News |
Eliem Therapeutics, Inc. will Change its Ticker to CLYM from ELYMOctober 2 - Finnhub |
|
 |
Eliem Therapeutics Changes Name to Climb BioOctober 2 - Yahoo |
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.October 2 - GlobeNewswire |
|
 |
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Sold by Driehaus Capital Management LLCSeptember 30 - Biztoc.com |
 |
Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231mSeptember 27 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 1.5M | 3.7M | -2.1M | -55M | -4.7M | -1.809 |
| Q1 '24 | 0 | 1.9M | -1.9M | -1.7M | -3M | -0.061 |
| Q4 '23 | 0 | 2M | -2M | -3.6M | -5.1M | -0.131 |
| Q3 '23 | 4,000 | 2.3M | -2.3M | -4M | -5M | -0.147 |
| Q2 '23 | 400,000 | 3.7M | -3.7M | -5.2M | -7.1M | -0.195 |
Insider Transactions View All
| Pimblett Emily filed to sell 7,564 shares at $8.1. September 20 '24 |
| Pimblett Emily filed to sell 7,573 shares at $8.2. September 20 '24 |
| Morisset Valerie filed to sell 31,317 shares at $8. July 23 '24 |
| Morisset Valerie filed to sell 61,317 shares at $8.1. July 23 '24 |
| Morisset Valerie filed to sell 150,322 shares at $7.1. July 23 '24 |
Similar companies
Read more about Eliem Therapeutics (ELYM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Eliem Therapeutics?
The Market Cap of Eliem Therapeutics is $343M.
What is the current stock price of Eliem Therapeutics?
Currently, the price of one share of Eliem Therapeutics stock is $5.11.
How can I analyze the ELYM stock price chart for investment decisions?
The ELYM stock price chart above provides a comprehensive visual representation of Eliem Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Eliem Therapeutics shares. Our platform offers an up-to-date ELYM stock price chart, along with technical data analysis and alternative data insights.
Does ELYM offer dividends to its shareholders?
As of our latest update, Eliem Therapeutics (ELYM) does not offer dividends to its shareholders. Investors interested in Eliem Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Eliem Therapeutics?
Some of the similar stocks of Eliem Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.